XTX Topco Ltd Purchases Shares of 18,401 Arvinas, Inc. (NASDAQ:ARVN)

XTX Topco Ltd purchased a new stake in Arvinas, Inc. (NASDAQ:ARVN) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 18,401 shares of the company’s stock, valued at approximately $453,000.

Several other large investors have also recently bought and sold shares of ARVN. FMR LLC increased its holdings in shares of Arvinas by 7.6% during the third quarter. FMR LLC now owns 2,883,604 shares of the company’s stock worth $71,023,000 after purchasing an additional 204,317 shares during the period. Braidwell LP increased its holdings in shares of Arvinas by 148.3% during the third quarter. Braidwell LP now owns 1,284,472 shares of the company’s stock worth $31,637,000 after purchasing an additional 767,242 shares during the period. ArrowMark Colorado Holdings LLC increased its holdings in shares of Arvinas by 1.4% during the third quarter. ArrowMark Colorado Holdings LLC now owns 1,244,450 shares of the company’s stock worth $30,651,000 after purchasing an additional 17,723 shares during the period. Candriam S.C.A. increased its holdings in shares of Arvinas by 32.0% during the second quarter. Candriam S.C.A. now owns 610,458 shares of the company’s stock worth $16,250,000 after purchasing an additional 147,904 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Arvinas by 6.8% during the second quarter. Dimensional Fund Advisors LP now owns 463,935 shares of the company’s stock worth $12,347,000 after purchasing an additional 29,635 shares during the period. 95.19% of the stock is owned by institutional investors.

Arvinas Stock Performance

NASDAQ ARVN opened at $19.50 on Friday. The firm’s fifty day moving average price is $25.52 and its two-hundred day moving average price is $26.01. The stock has a market cap of $1.34 billion, a PE ratio of -4.18 and a beta of 1.82. Arvinas, Inc. has a fifty-two week low of $18.51 and a fifty-two week high of $53.08.

Arvinas (NASDAQ:ARVN) last posted its earnings results on Wednesday, October 30th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.20. The company had revenue of $102.40 million for the quarter, compared to the consensus estimate of $60.56 million. During the same period in the previous year, the firm posted ($1.18) EPS. The business’s quarterly revenue was up 196.0% compared to the same quarter last year. As a group, sell-side analysts predict that Arvinas, Inc. will post -3.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ARVN. Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a research report on Monday, September 9th. Guggenheim restated a “buy” rating on shares of Arvinas in a research report on Thursday. HC Wainwright restated a “buy” rating and set a $87.00 price objective on shares of Arvinas in a research report on Wednesday. BMO Capital Markets lowered their price objective on shares of Arvinas from $90.00 to $88.00 and set an “outperform” rating for the company in a research report on Wednesday, November 20th. Finally, BTIG Research began coverage on shares of Arvinas in a research report on Tuesday, December 10th. They set a “buy” rating and a $69.00 price objective for the company. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, Arvinas currently has a consensus rating of “Moderate Buy” and a consensus target price of $63.50.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.